HCG Expands Cancer Care Network With Two New Advanced Centres In Bengaluru
Together, they will accommodate a total of 125 beds, providing high-precision diagnosis and personalised treatment plans
Healthcare Global (HCG) has announced a significant expansion in Bengaluru with the inauguration of two new comprehensive cancer care centres in Whitefield and North Bengaluru. These strategically positioned facilities mark the third and fourth additions to HCG's hospital network in Bengaluru and are slated to commence operations in early 2025, the hospital said in a press statement on Tuesday.
The new centres, strategically situated near rapidly growing prime residential areas, aim to bring advanced cancer care closer to the local community. Equipped with new technology and staffed with experienced oncologists, the Whitefield and North Bengaluru centres will offer a complete range of cancer care services under one roof. Together, they will accommodate a total of 125 beds, providing high-precision diagnosis and personalised treatment plans, the statement from the hospital read.
B S Ajaikumar, Executive Chairman of Healthcare Global, emphasised the company's commitment to extending world-class cancer care to a broader population as Bengaluru continues to evolve. He stated that the expansion reflects HCG's deep-rooted connection to the city and its dedication to enhancing healthcare accessibility for the local community.
Raj Gore, CEO of HealthCare Global, highlighted the organisation's focus on growth and consolidation in a sector characterised by demand-supply gaps and fragmentation. He reiterated HCG's commitment to investing in new infrastructure, advanced treatments, and cutting-edge technology to ensure comprehensive and quality cancer care services closer to patients in and around Bengaluru.
With the introduction of the MR LINAC radiation system at its North Bangalore facility, HCG aims to revolutionise radiation therapy in the state. This innovative technology integrates magnetic resonance imaging (MRI) with a linear accelerator (LINAC), promising improved clinical outcomes, decreased side effects, and reduced treatment duration, the statement added.
